keyword
https://read.qxmd.com/read/38515348/clinical-dose-rationale-of-tislelizumab-in-patients-with-solid-or-hematological-advanced-tumors
#21
JOURNAL ARTICLE
Tian Yu, Xiangyu Liu, Chi-Yuan Wu, Zhiyu Tang, Hongwei Wang, Patrick Schnell, Ya Wan, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman, Nageshwar Budha
Tislelizumab, an anti-programmed cell death protein 1 monoclonal antibody, has demonstrated improved survival benefits over standard of care for multiple cancer indications. We present the clinical rationale and data supporting tislelizumab dose recommendation in patients with advanced tumors. The phase I, first-in-human, dose-finding BGB-A317-001 study (data cutoff [DCO]: August 2017) examined the following tislelizumab dosing regimens: 0.5-10 mg/kg every 2 weeks (q2w), 2-5 mg/kg q2w or q3w, and 200 mg q3w...
March 2024: Clinical and Translational Science
https://read.qxmd.com/read/38515220/diagnostic-dilemma-in-maxillofacial-pathologies-a-case-series
#22
JOURNAL ARTICLE
Pavithra Sarda, Prashanthi Gurram, Karthik Ramakrishnan, Vivek Narayanan, Saravanan Chandran, Divya Vinayachandran
BACKGROUND: Head and neck are a site of numerous pathologies with different aetiologies and presentations. Rare pathologies, although infrequent still do exist. Diagnostic dilemma in maxillofacial pathologies can be the most challenging situation. Dealing with uncertainty, although difficult, is a reality in surgical practice. Being thorough, attentive to details and clues, and maintaining an open mind are critical strategies in the approach to such a patient. CASE PRESENTATION: In our paper we are reporting a spectrum of 4 unusual variants of head and neck pathologies, whose age and sex were 52 years/ M, 37 years/F, 41 years/ F, 30 years/F respectively...
March 21, 2024: Journal of Medical Case Reports
https://read.qxmd.com/read/38513186/increasing-annual-cancer-incidence-in-patients-age-20-49-years-a-real-data-study
#23
JOURNAL ARTICLE
Nuria Ribelles, Javier Pascual, Laura Galvez-Carvajal, Sofía Ruiz-Medina, Javier Garcia-Corbacho, Jose Carlos Benitez, Maria Emilia Dominguez-Recio, Esperanza Torres, Lucia Oliva, Manuel Zalabardo, Antonio Rueda, Emilio Alba
PURPOSE: Data from population-based studies have shown an increased incidence of certain types of neoplasms in patients younger than 50 years (early-onset cancer [EOC]); however, little information is derived from other real-world data sources. In a nonpopulation registry, we analyzed changes in the incidence of several neoplasms in successive generations. METHODS: This cross-sectional study included all patients with a cancer diagnosis registered in one university hospital in Málaga, Spain, between 1998 and 2021, and 18 neoplasms were analyzed...
March 2024: JCO global oncology
https://read.qxmd.com/read/38513161/cancer-treatment-disparities-in-people-with-hiv-in-the-united-states-2001-2019
#24
JOURNAL ARTICLE
Jennifer K McGee-Avila, Gita Suneja, Eric A Engels, Anne F Rositch, Marie-Josephe Horner, Qianlai Luo, Meredith S Shiels, Jessica Y Islam
PURPOSE: People with HIV (PWH) have worse cancer outcomes, partially because of inequities in cancer treatment. We evaluated cancer treatment disparities among PWH, including an assessment of changes in disparities over time. METHODS: We used data from the HIV/AIDS Cancer Match Study, a population-based HIV and cancer registry linkage to examine diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and cancers of the cervix, lung, anus, prostate, colon, and female breast...
March 21, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38512531/primary-vs-pre-emptive-anti-seizure-medication-prophylaxis-in-anti-cd19-car-t-cell-therapy
#25
JOURNAL ARTICLE
Umberto Pensato, Federica Pondrelli, Chiara de Philippis, Gian Maria Asioli, Alessandra Crespi, Alessandro Buizza, Daniele Mannina, Beatrice Casadei, Enrico Maffini, Laura Straffi, Simona Marcheselli, Pier Luigi Zinzani, Francesca Bonifazi, Maria Guarino, Stefania Bramanti
INTRODUCTION: Seizures may occur in up to 30% of non-Hodgkin lymphoma patients who received anti-CD19 CAR T-cell therapy, yet the optimal anti-seizure medication (ASM) prevention strategy has not been thoroughly investigated. METHODS: Consecutive patients affected by refractory non-Hodgkin lymphoma who received anti-CD19 CAR T-cells were included. Patients were selected and assessed using similar internal protocols. ASM was started either as a primary prophylaxis (PP-group) before CAR T-cells infusion or as a pre-emptive therapy (PET-group) only upon the onset of neurotoxicity development...
March 21, 2024: Neurological Sciences
https://read.qxmd.com/read/38511807/myelotoxicity-and-kidney-dysfunction-related-to-the-use-of-trimethoprim-sulfamethoxazole-for-the-treatment-of-pneumocystis-jirovecii-pneumonia-a-case-report-of-severe-adverse-events-with-a-common-drug
#26
Isabel Cristina Melo Mendes, Roxana Flores Mamani, David Richer Araujo Coelho, Clarisse Pimentel
Trimethoprim-sulfamethoxazole (TMP-SMX) is the primary therapeutic option for Pneumocystis jirovecii pneumonia (PCP). Gastrointestinal symptoms and cutaneous rash are common side effects, with hyperkalemia being uncommon in patients without kidney dysfunction, and myelotoxicity being even rarer. We present the case of a male patient with hypertension and a recent diagnosis of non-Hodgkin lymphoma, undergoing rituximab treatment for two months. He was admitted to the intensive care unit due to dyspnea, tachypnea, and pleuritic pain, requiring mechanical ventilation...
2024: Revista do Instituto de Medicina Tropical de São Paulo
https://read.qxmd.com/read/38511022/a-case-of-medullary-carcinoma-of-colon-morphologically-resembling-non-hodgkin-s-lymphoma
#27
Md Ali Osama, Shashi Dhawan, Arvind Kumar
Medullary carcinoma of the colon is an unusual and unique histologic subtype of colorectal cancer. It is strongly associated with microsatellite instability, most commonly loss of MLH1 indicative of deficient mismatch repair proteins. Diagnosis is challenging as they do not display the usual histological pattern. Immunohistochemical staining also shows unusual findings like negativity for CD20 and CDX2. Here, we explore an intriguing case of medullary carcinoma of colon which showed loss of MSH2 and MSH6 and a morphology reminiscent of Non-Hodgkin's lymphoma...
March 2024: Indian Journal of Surgical Oncology
https://read.qxmd.com/read/38510293/statin-use-is-associated%C3%A2-with-reduced-heart%C3%A2-failure-and-risk-of-death-in-non-hodgkin-lymphoma
#28
JOURNAL ARTICLE
Chao-Yu Chen, Wei-Ting Chang, Hui-Wen Lin, Sheng-Hsiang Lin, Yi-Heng Li
No abstract text is available yet for this article.
February 2024: JACC CardioOncology
https://read.qxmd.com/read/38510239/remission-of-relapsed-refractory-classical-hodgkin-lymphoma-induced-by-brentuximab-vedotin-and-pembrolizumab-combination-after-allogeneic-hematopoietic-stem-cell-transplantation-a-case-report
#29
Federica Giannotti, Carmen De Ramon Ortiz, Federico Simonetta, Sarah Morin, Chiara Bernardi, Stavroula Masouridi-Levrat, Yves Chalandon, Anne-Claire Mamez
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programmed cell death protein-1 (PD-1) blocking agents have demonstrated clinical activity with durable responses in relapsed/refractory (r/r) HL. However, patients with a history of allo-HSCT were frequently excluded from clinical trials due to concerns about the risk of graft-versus-host disease (GVHD)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38508620/rituximab-combined-anthracycline-free-chemotherapy-in-newly-diagnosed-paediatric-and-adolescent-patients-with-non-high-risk-aggressive-mature-b-cell-lymphoma-protocol-for-a-single-arm-open-label-multicentre-phase-ii-study-the-japan-children-s-cancer-group-multicentre
#30
JOURNAL ARTICLE
Masahiro Sekimizu, Reiji Fukano, Yuhki Koga, Tetsuo Mitsui, Naoto Fujita, Takeshi Mori, Daiki Hori, Makito Tanaka, Kentaro Ohki, Hideto Iwafuchi, Atsuko Nakazawa, Tetsuya Mori, Ryoji Kobayashi, Hiroya Hashimoto, Akiko M Saito, Michi Kamei
INTRODUCTION: Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure rate in good-risk patients. Although the addition of rituximab to standard lymphome Malin B (LMB) chemotherapy markedly prolongs event-free survival and overall survival in high-risk patients, the benefit of rituximab in good-risk patients remains to be elucidated. This clinical trial will examine whether the addition of rituximab eliminates anthracyclines in good-risk patients without compromising treatment outcomes...
March 19, 2024: BMJ Open
https://read.qxmd.com/read/38506403/assessment-of-bone-marrow-involvement-in-b-cell-non-hodgkin-lymphoma-using-immunoglobulin-gene-rearrangement-analysis-with-next-generation-sequencing
#31
JOURNAL ARTICLE
Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Chul Won Choi, Ha Nui Kim, Jung Ah Kwon, Soo-Young Yoon, Jung Yoon
BACKGROUND: Assessment of bone marrow involvement (BMI) in non-Hodgkin lymphoma (NHL) is crucial for determining patient prognosis and treatment strategy. We assessed the prognostic value of next-generation sequencing (NGS)-based immunoglobulin (Ig) gene clonality analysis as an ancillary test for BMI evaluation in NHL. METHODS: A retrospective cohort of 124 patients newly diagnosed with B-cell NHL between 2019 and 2022 was included. NGS-based Ig clonality analysis was conducted using LymphoTrak IGH FR1 Assay and IGK Assay (Invivoscribe Technologies, San Diego, CA, USA) on BM aspirate samples, and the results were compared with those of histopathological BMI (hBMI)...
March 20, 2024: Journal of Clinical Laboratory Analysis
https://read.qxmd.com/read/38504844/blastoid-variant-of-mantle-cell-lymphoma-with-extranodal-presentation-and-aberrant-cd10-expression
#32
Arthy Raman, Sree Rekha Jinkala, Roobashri Murugan, Prabhu Manivannan
Mantle cell lymphoma (MCL) constitutes 3%-10% of non-Hodgkin lymphoma and is characterized by t (11:14)(q13;q32). The common presentation is generalized lymphadenopathy with weight loss, infrequently night sweats, and fever. Among histological subtypes of MCL, the blastoid variant of MCL constitutes 10%-15% of all the cases. It is challenging to diagnose the blastoid variant of MCL based on its morphology alone as it mimics large B-cell lymphoma. Hence, the immunophenotyping and molecular studies aid in its correct diagnosis...
2024: International Journal of Applied and Basic Medical Research
https://read.qxmd.com/read/38502227/brentuximab-vedotin-and-chemotherapy-in-relapsed-refractory-hodgkin-lymphoma-a-propensity-score-matched-analysis
#33
JOURNAL ARTICLE
Julia Driessen, Fer de Wit, Alex F Herrera, Pier Luigi Zinzani, Ann S LaCasce, Peter D Cole, Craig H Moskowitz, Ramón García-Sanz, Michael Fuchs, Horst Mueller, Peter Borchmann, Armando Santoro, Heiko Schöder, Josée M Zijlstra, Barbara A Hutten, Alison J Moskowitz, Marie José Kersten
Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem-cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no head-to-head comparisons with standard salvage chemotherapy have been performed. This study presents a propensity score-matched analysis encompassing individual patient data from ten clinical trials to evaluate the impact of BV in transplant-eligible R/R cHL patients. We included 768 patients, of whom 386 were treated with BV +/- chemotherapy (BV-cohort), while 382 received chemotherapy alone (chemo-cohort)...
March 19, 2024: Blood Advances
https://read.qxmd.com/read/38496566/epstein-barr-virus-orchestrates-spatial-reorganization-and-immunomodulation-within-the-classic-hodgkin-lymphoma-tumor-microenvironment
#34
Yao Yu Yeo, Huaying Qiu, Yunhao Bai, Bokai Zhu, Yuzhou Chang, Jason Yeung, Hendrik A Michel, Kyle Wright, Muhammad Shaban, Sam Sadigh, Dingani Nkosi, Vignesh Shanmugam, Philip Rock, Stephanie Pei Tung Yiu, Precious Cramer, Julia Paczkowska, Pierre Stephan, Guanrui Liao, Amy Y Huang, Hongbo Wang, Han Chen, Leonie Frauenfeld, Bidisha Mitra, Benjamin E Gewurz, Christian M Schürch, Bo Zhao, Garry P Nolan, Baochun Zhang, Alex K Shalek, Michael Angelo, Faisal Mahmood, Qin Ma, W Richard Burack, Margaret A Shipp, Scott J Rodig, Sizun Jiang
Classic Hodgkin Lymphoma (cHL) is a tumor composed of rare malignant Hodgkin and Reed-Sternberg (HRS) cells nested within a T-cell rich inflammatory immune infiltrate. cHL is associated with Epstein-Barr Virus (EBV) in 25% of cases. The specific contributions of EBV to the pathogenesis of cHL remain largely unknown, in part due to technical barriers in dissecting the tumor microenvironment (TME) in high detail. Herein, we applied multiplexed ion beam imaging (MIBI) spatial pro-teomics on 6 EBV-positive and 14 EBV-negative cHL samples...
March 7, 2024: bioRxiv
https://read.qxmd.com/read/38495131/effect-of-rituximab-on-immune-status-in-children-with-aggressive-mature-b-cell-lymphoma-leukemia-a-prospective-study-from-cccg-bnhl-2015
#35
JOURNAL ARTICLE
Jiajia Dong, Zhou Xu, Xia Guo, Fanghua Ye, Chenying Fan, Ju Gao, Yijin Gao, Liangchun Yang
BACKGROUND: Limited research has been conducted on the impact of rituximab on immune function and the incidence of side effects in children undergoing combination chemotherapy for aggressive mature B-cell lymphoma/leukemia. METHODS: Clinical data from 85 patients with primary pediatric aggressive mature B-cell lymphoma/leukemia, treated according to the Chinese Children's Cancer Group (CCCG)-mature B-cell non-Hodgkin lymphoma (BNHL)-2015 protocol from June 1, 2015, to December 1, 2022, were collected from three tertiary medical centers in China...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38494543/matching-adjusted-indirect-comparison-of-brexucabtagene-autoleucel-zuma-2-and-pirtobrutinib-bruin-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-previously-treated-with-a-covalent-bruton-tyrosine-kinase%C3%A2-inhibitor
#36
JOURNAL ARTICLE
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
INTRODUCTION: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) often require multiple lines of treatment and have a poor prognosis, particularly after failing covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy. Newer treatments such as brexucabtagene autoleucel (brexu-cel, chimeric antigen receptor T cell therapy) and pirtobrutinib (non-covalent BTKi) show promise in improving outcomes. METHODS: Without direct comparative evidence, an unanchored matching-adjusted indirect comparison was conducted to estimate the relative treatment effects of brexu-cel and pirtobrutinib for post-cBTKi R/R MCL...
March 18, 2024: Advances in Therapy
https://read.qxmd.com/read/38494294/hematologic-malignancies-and-hematopoietic-stem-cell-transplantation
#37
REVIEW
Chiara Briani, Andrea Visentin
Paraneoplastic neurologic syndromes are rarely associated with hematologic malignancies. In their rarity, lymphomas are the diseases with more frequent paraneoplastic neurologic syndrome. High-risk antibodies are absent in most lymphoma-associated paraneoplastic neurologic syndromes, with the exception of antibodies to Tr/DNER in paraneoplastic cerebellar degeneration, mGluR5 in limbic encephalitis, and mGluR1 in some cerebellar ataxias. Peripheral nervous system paraneoplastic neurologic syndromes are rare and heterogeneous, with a prevalence of demyelinating polyradiculoneuropathy in non-Hodgkin lymphoma...
2024: Handbook of Clinical Neurology
https://read.qxmd.com/read/38494279/paraneoplastic-movement-disorders
#38
REVIEW
Andrew McKeon, Jennifer Tracy
Paraneoplastic movement disorders are diverse autoimmune neurological illnesses occurring in the context of systemic cancer, either in isolation or as part of a multifocal neurological disease. Movement phenomena may be ataxic, hypokinetic (parkinsonian), or hyperkinetic (myoclonus, chorea, or other dyskinetic disorders). Some disorders mimic neurodegenerative or hereditary illnesses. The subacute onset and coexisting nonclassic features of paraneoplastic disorders aid distinction. Paraneoplastic autoantibodies provide further information regarding differentiating cancer association, disease course, and treatment responses...
2024: Handbook of Clinical Neurology
https://read.qxmd.com/read/38494276/paraneoplastic-cerebellar-and-brainstem-disorders
#39
REVIEW
Justin R Abbatemarco, Christian A Vedeler, John E Greenlee
Paraneoplastic cerebellar and brainstem disorders are a heterogeneous group that requires prompt recognition and treatment to help prevent irreversible neurologic injury. Paraneoplastic cerebellar degeneration is best characterized by Yo antibodies in patients with breast or ovarian cancer. Tr (DNER) antibodies in patients with Hodgkin lymphoma can also present with a pure cerebellar syndrome and is one of the few paraneoplastic syndromes found with hematological malignancy. Opsoclonus-myoclonus-ataxia syndrome presents in both pediatric and adult patients with characteristic clinical findings...
2024: Handbook of Clinical Neurology
https://read.qxmd.com/read/38493778/ambulatory-routine-care-in-oncology-in-germany-real-world-survival-data
#40
JOURNAL ARTICLE
Norbert Marschner, Wolfgang Knauf
INTRODUCTION: Survival data reported by randomised controlled trials are collected in a highly selected patient population and can thus only be transferred to a limited extent to real-world patients: the patients in routine care are mostly older, present with more comorbidities and a worse general state of health. This so-called efficacy-effectiveness gap typically results in inferior survival data in routine healthcare. METHODS: Six prospective clinical tumour registries recruited a total of 11,679 patients receiving systemic therapy in haemato-oncological practices in Germany between 2006 and 2020...
March 15, 2024: Oncology Research and Treatment
keyword
keyword
12259
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.